Drugs / 18F-Fludarabine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05390814 | Dec 2023 → Dec 2024 | primary central nervous system lymphoma | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 1 | NCT03832127 | Sep 2022 → Sep 2024 overdue | plasma cell myeloma | Nantes University Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-Fludarabine | “[18F]-Fludarabine is a new radiopharmaceutical developed for PET imaging of lymphomas.” NCT05390814 ↗ |
| Modality | Diagnostic / imaging agent | “PET with 18F-Fludarabine” NCT03832127 ↗ |